Free Trial
NASDAQ:THAR

Tharimmune Q3 2024 Earnings Report

Tharimmune logo
$1.24 -0.01 (-0.40%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$1.26 +0.02 (+1.94%)
As of 08/1/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tharimmune EPS Results

Actual EPS
-$2.45
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Tharimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tharimmune Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Tharimmune's Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Monday, August 11, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Tharimmune Earnings Headlines

Tharimmune Completes Private Placement Agreement
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
Tharimmune CFO Don Kim Resigns
See More Tharimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email.

About Tharimmune

Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

View Tharimmune Profile

More Earnings Resources from MarketBeat